Subject(s)
Antihypertensive Agents/therapeutic use , Coronary Artery Disease/epidemiology , Hypertension/drug therapy , Hypertension/epidemiology , Practice Guidelines as Topic , American Heart Association , Blood Pressure Determination/methods , Comorbidity , Coronary Artery Disease/diagnosis , Coronary Artery Disease/drug therapy , Female , Humans , Hypertension/diagnosis , Male , Prognosis , Risk Assessment , Severity of Illness Index , Societies, Medical , Survival Rate , Treatment Outcome , United StatesSubject(s)
Antihypertensive Agents/therapeutic use , Coronary Artery Disease/complications , Hypertension/therapy , Age Factors , Aged , Anticoagulants/therapeutic use , Antihypertensive Agents/classification , Clinical Trials as Topic , Cohort Studies , Combined Modality Therapy , Comorbidity , Coronary Artery Disease/epidemiology , Denervation , Diet, Sodium-Restricted , Evidence-Based Medicine , Exercise Therapy , Goals , Hemodynamics , Humans , Hypertension/epidemiology , Hypertension/genetics , Hypertension/physiopathology , Hypertension, Renal/physiopathology , Hypertension, Renal/surgery , Middle Aged , Multicenter Studies as Topic , Prevalence , Risk Factors , Risk Reduction BehaviorSubject(s)
Antihypertensive Agents/administration & dosage , Coronary Artery Disease/drug therapy , Coronary Artery Disease/epidemiology , Hypertension/drug therapy , Hypertension/epidemiology , Practice Guidelines as Topic , American Heart Association , Comorbidity , Coronary Artery Disease/diagnosis , Female , Humans , Hypertension/diagnosis , Male , Prognosis , Risk Assessment , Societies, Medical , Survival Rate , United StatesSubject(s)
Acute Coronary Syndrome , Coronary Artery Disease , American Heart Association , Cardiology/standards , Female , Humans , Male , Societies, Medical , United StatesSubject(s)
Acute Coronary Syndrome/therapy , American Heart Association , Cardiology/standards , Coronary Artery Disease/therapy , Research Design/standards , Acute Coronary Syndrome/diagnosis , Acute Coronary Syndrome/epidemiology , Advisory Committees/standards , Coronary Artery Disease/diagnosis , Coronary Artery Disease/epidemiology , Disease Management , Foundations/standards , Humans , Research Report/standards , Treatment Outcome , United States/epidemiologyABSTRACT
The formation of blood clots is a significant threat to individuals with limited mobility, whether in the hospital or recovering in an outpatient setting. Prevention of deep vein thrombosis and pulmonary embolism has been found to be cost-effective when compared with treating an existing thrombosis. Despite these positive findings, compliance with the clinical practice guidelines is less than ideal. The National Consensus Standards for the Prevention and Care of Deep Vein Thrombosis Project identified 4 domains to address the problem of noncompliance related to venous thromboembolism: risk assessment, diagnosis, prevention, and treatment.The objective of treating an existing deep vein thrombosis is to prevent further extension of the clot. Pharmacological interventions for both prevention and treatment include unfractionated heparin, low-molecular-weight heparin, selective factor Xa inhibitors, and vitamin K antagonists; nonpharmacological interventions include mechanical measures, such as inferior vena cava filters, graduated compression stockings, and intermittent pneumatic compression devices. Pharmacological interventions interfere with various factors of the coagulation cascade. An adverse effect commonly associated with these drugs is excessive bleeding. The mechanism of action surrounding mechanical interventions is to increase venous return and decrease the risk of pooling of blood in the leg veins. These interventions are effective only if implemented. Clinical application of clinical practice guidelines is imperative to protect patients at risk.